Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
Investing.com - TD Cowen has reiterated a Buy rating with a $14.00 price target on Ocular Therapeutix (NASDAQ:OCUL), currently trading at $11.66 and near its 52-week high of $12.35, as the company awaits Phase III trial results. According to InvestingPro data, analyst targets range from $14 to $22, suggesting potential upside.
The firm noted that topline data from the SOL-1 trial is expected in Q1 2026, following a trial extension implemented in March to evaluate re-dosing protocols that could support either a six-month or 12-month superiority label.
Ocular management has confirmed that most masked rescues in the trial have been performed according to pre-specified protocol criteria, which TD Cowen views as positive for the final analysis since only an "immaterial number" of patients would be excluded.
The trial is reportedly overpowered, requiring only a 15% difference at 36 weeks to achieve statistical significance, while historical data suggests a potential 50% difference between Axpaxli and Eylea based on rescue rates.
Company management has expressed confidence that the masked data remains consistent with expectations of a 40-60% delta between treatment arms, based on the number, cadence, and nature of rescues observed in the ongoing trial.
In other recent news, Ocular Therapeutix reported its second-quarter 2025 earnings, revealing a mixed financial performance. The company posted a revenue of $13.5 million, narrowly missing the projected $13.6 million. Despite this, revenue exceeded Raymond (NSE:RYMD) James’ estimate of $12.0 million, highlighting some positive aspects. However, Ocular Therapeutix recorded a diluted earnings per share loss of $(0.39), which was worse than the forecasted $(0.35) loss. Expenses were notably higher than expected, totaling $51.1 million compared to the anticipated $43.1 million. Analysts from Clear Street and Raymond James maintained their positive outlook on the company, reiterating Buy and Strong Buy ratings with price targets of $18 and $19, respectively. Revenue growth was primarily driven by Dextenza, with unit sales increasing 5% year-over-year, although there were challenges due to reimbursement conditions. These developments reflect the ongoing financial challenges and opportunities for Ocular Therapeutix.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.